Next Science (ASX:NXS) said the derivative complaint filed by former employee Michael Morello in Florida's Duval County Court has been dismissed for lack of standing, according to a Monday filing with the Australian bourse.
The complaint alleges that the company's Xbio technology has not been approved by the US Food and Drug Administration for biofilm eradication and that the company failed to address safety concerns regarding its Xperience surgical solution in breast implant procedures, the company said in a Jan. 8 filing.
The litigation initiated by the company against Morello and other former employees for breach of post-employment restraints is underway.
Next Science's shares rose more than 4% in midday trade Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。